Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | HCK | P08631 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.48 |
| ▸ | PRKDC | P78527 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.41 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876083 | 0.90 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL30218820 | 0.86 | SCN9A (0.45) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL28917933 | 0.86 | SCN9A (0.45) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL13247916 | 0.85 | PIK3CD (0.51) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL3902843 | 0.85 | PIK3CD (0.51) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL2458509 | 0.85 | ACLY (0.52) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL22130186 | 0.84 | PIK3CD (0.55) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL31253112 | 0.82 | PIK3CD (0.49) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL3964381 | 0.82 | PIK3CD (0.52) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL30524309 | 0.82 | CDC7 (0.40) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1687313-A1 | INDOLYL-THIEN 3,4-B]PYRAZIN-3-ONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | US | disclosed |
| EP-1565455-A1 | INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005051957-A1 | INDOLYL-THIENO`3,4-B!PYRAZIN-3-ONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004043950-A1 | INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | MKI67, CDK4, PGF | PIK3CD 426/4885ABL1 173/4885EGFR 554/4885 |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | MKI67, VEGFA, FLT1 | PIK3CD 624/4885ABL1 868/4885EGFR 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.